Tomoya Takemoto1, Masayuki Baba1, Kazumasa Yokoyama2, Kohei Kitagawa1, Kazuki Nagayasu1,3, Yukio Ago4, Kaoru Seiriki1,5, Atsuko Hayata-Takano1,6, Atsushi Kasai1, Daisuke Mori7,8, Norio Ozaki7, Kazuhiro Takuma6,9, Ryota Hashimoto10, Hitoshi Hashimoto11,12,13,14,15,16, Takanobu Nakazawa17,18,19. 1. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. 2. Discovery Accelerator, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, 305-8585, Japan. 3. Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan. 4. Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Hiroshima, 734-8553, Japan. 5. Interdisciplinary Program for Biomedical Sciences, Institute for Transdisciplinary Graduate Degree Programs, Osaka University, Suita, Osaka, 565-0871, Japan. 6. United Graduate School of Child Development, Molecular Research Center for Children's Mental Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan. 7. Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan. 8. Brain and Mind Research Center, Nagoya University, Nagoya, Aichi, 466-8550, Japan. 9. Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan. 10. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan. 11. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp. 12. United Graduate School of Child Development, Molecular Research Center for Children's Mental Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp. 13. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan. hasimoto@phs.osaka-u.ac.jp. 14. Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp. 15. Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp. 16. Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp. 17. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. tn207427@nodai.ac.jp. 18. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan. tn207427@nodai.ac.jp. 19. Laboratory of Molecular Biology, Department of Bioscience, Graduate School of Life Sciences, Tokyo University of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku, Tokyo, 156-8502, Japan. tn207427@nodai.ac.jp.
Correction to: Molecular Brain (2022) 15:26 https://doi.org/10.1186/s13041-022-00915-w.
Following publication of the original article [1], a typesetting error was identified in the article title.The article title was incorrectly published as: Molecular brain (micro report) oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome.The article title should read: Oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome.The error has been corrected and the original article has been updated. The publisher apologises to the authors and readers for the inconvenience caused by this mistake.